Skip to main content

Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex.

Sajdel-Sulkowska EM, Marotta CA

Publication: Science (1984) • Vol 225 • Page 947-9PMID: 6206567View on PubMed

Purpose

The purpose of this paper was to determine the effect of postmortem interval (PMI) and Alzheimer's disease on total and polyadenylated (poly(A)) RNA yield and ribonuclease (RNase) activity in brain cortex.

Conclusion

No correlation between total or poly(A) RNA yield and postmortem intervals of 3.5-25 h was identified. Total and poly(A) RNA differed significantly among disease states, as the cerebral cortex of Alzheimer's disease brains yielded only 54.7% of the total and 35.7% of the poly(A) RNA obtained from control specimens. Alkaline RNase activity, which also differed among disease states, was 1.87 fold higher in Alzheimer's disease brains than normal controls. One of the six Alzheimer's disease specimens had values within the normal range for both RNase activity and RNA yield. The addition of p-chloromecuribenzoate (PCMB), a chemical blocker of endogenous inhibitors of RNasaes, elicited a 1.33 fold increase in alkaline RNase activity in control brains, but a decrease in all Alzheimer's disease brains examined reducing activity to less than 1% of that observed prior to treatment. Acid RNAse levels were independent of PMI, but higher in Alzheimer disease cortices compared to normal controls, and inducible by PCMB treatment in all specimens. The authors conclude that PMI has no effect on RNA yield or RNase activity, but that Alzheimer's disease alters the RNase complex increasing overall activity and thereby decreasing total and poly(A) RNA levels.

Studies (1)

Purpose

The purpose of this study was to determine the effect of PMI (3.5-15 h) and Alzheimer's disease on total and poly(A) RNA yield and RNase activity in the cortex.

Summary of Findings

No correlation between total or poly(A) RNA yield and postmortem intervals of 3.5-25 h was identified. Total and poly(A) RNA differed significantly among disease states, as the cerebral cortex of Alzheimer's disease brains yielded only 54.7% of the total and 35.7% of the poly(A) RNA obtained from control specimens. Alkaline RNase activity, which also differed among disease states, was 1.87 fold higher in Alzheimer's disease brains than normal controls. One of the six Alzheimer's disease specimens had values within the normal range for both RNase activity and RNA yield. The addition of p-chloromecuribenzoate (PCMB), a chemical blocker of endogenous inhibitors of RNasaes, elicited a 1.33 fold increase in alkaline RNase activity in control brains, but a decrease in all Alzheimer's disease brains examined reducing activity to less than 1% of that observed prior to treatment. Acid RNAse levels were independent of PMI, but higher in Alzheimer disease cortices compared to normal controls, and inducible by PCMB treatment in all specimens. The authors conclude that PMI has no effect on RNA yield or RNase activity, but that Alzheimer's disease alters the RNase complex increasing overall activity and thereby decreasing total and poly(A) RNA levels.
  • Biospecimens

    TissueBrain
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
    Autopsy
    Alzheimer's Disease
  • Platforms

    RNASpectrophotometry
    ProteinEnzyme assay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Alzheimer's disease
    Normal control -no neuropsychiatric disease
    PreaquisitionPostmortem interval
    3.5-25 h